Suppr超能文献

在加拿大,致幻剂的使用与非法药物使用者每日阿片类药物使用量减少有关。

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.

机构信息

Department of Medicine, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z9, Canada; BC Centre on Substance Use, 1045 Howe St. Vancouver, BC V6Z 1Y6, Canada.

BC Centre on Substance Use, 1045 Howe St. Vancouver, BC V6Z 1Y6, Canada; Faculty of Heath Sciences, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 1S6, Canada.

出版信息

Int J Drug Policy. 2022 Feb;100:103518. doi: 10.1016/j.drugpo.2021.103518. Epub 2021 Nov 7.

Abstract

BACKGROUND

Research into the therapeutic and naturalistic uses of psychedelics for improving outcomes related to mental health disorders has generated increasing interest in recent years. While controlled clinical trials of psychedelics have signaled benefits for treating substance use disorders, this area has not been well studied in the context of naturalistic psychedelic use. This study sought to investigate the possible relationship between recent naturalistic psychedelic use and subsequent daily illicit opioid use among people who use drugs (PWUD).

METHODS

Data (2006-2018) were drawn from three harmonized prospective cohorts of community-recruited PWUD in Vancouver, Canada. We used multivariable generalized linear mixed-effects modeling (GLMM) to estimate the independent association between psychedelic use and subsequent daily illicit opioid use.

RESULTS

Among 3813 PWUD at baseline, 1093 (29%) reported daily use of illicit opioids and 229 (6%) reported psychedelic use in the past six months. Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use (Adjusted Odds Ratio: 0.45; 95% Confidence Interval: 0.29 to 0.70).

CONCLUSION

While confirmation in other settings is required, these findings align with growing evidence that psychedelic use may be associated with detectable reductions in subsequent substance use including illicit opioid use.

摘要

背景

近年来,人们对研究迷幻药在改善与心理健康障碍相关的治疗和自然使用方法的兴趣日益浓厚。虽然迷幻药的对照临床试验表明其对治疗物质使用障碍具有益处,但在自然使用迷幻药的背景下,这方面的研究还不够充分。本研究旨在调查近期自然使用迷幻药与随后的每日非法阿片类药物使用之间可能存在的关系,这些人是吸毒者(PWUD)。

方法

数据(2006-2018 年)来自加拿大温哥华三个社区招募的吸毒者的三个协调前瞻性队列。我们使用多变量广义线性混合效应模型(GLMM)来估计迷幻药使用与随后的每日非法阿片类药物使用之间的独立关联。

结果

在基线时的 3813 名吸毒者中,有 1093 人(29%)报告每日使用非法阿片类药物,229 人(6%)报告在过去六个月内使用过迷幻药。在调整了一系列潜在混杂因素后,在研究随访期间,迷幻药的使用与随后每日阿片类药物使用的可能性显著降低独立相关(调整后的优势比:0.45;95%置信区间:0.29 至 0.70)。

结论

虽然需要在其他环境中得到证实,但这些发现与越来越多的证据一致,即迷幻药的使用可能与随后的物质使用包括非法阿片类药物的使用明显减少有关。

相似文献

1
Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.
Int J Drug Policy. 2022 Feb;100:103518. doi: 10.1016/j.drugpo.2021.103518. Epub 2021 Nov 7.
3
Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis.
PLoS Med. 2019 Nov 19;16(11):e1002967. doi: 10.1371/journal.pmed.1002967. eCollection 2019 Nov.
5
Increasing availability of illicit and prescription opioids among people who inject drugs in a Canadian setting, 2010-2014.
Am J Drug Alcohol Abuse. 2018;44(3):368-377. doi: 10.1080/00952990.2017.1376678. Epub 2017 Oct 19.
6
The association of psychedelic use and opioid use disorders among illicit users in the United States.
J Psychopharmacol. 2017 May;31(5):606-613. doi: 10.1177/0269881117691453. Epub 2017 Feb 14.
8
Effect of witnessing an overdose on the use of drug checking services among people who use illicit drugs in Vancouver, Canada.
Am J Drug Alcohol Abuse. 2020 Jul 3;46(4):506-511. doi: 10.1080/00952990.2019.1708087. Epub 2020 Jan 26.
10
Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting.
Drug Alcohol Depend. 2020 Jul 1;212:108005. doi: 10.1016/j.drugalcdep.2020.108005. Epub 2020 Apr 25.

引用本文的文献

2
Exploring the therapeutic potential of psychedelics in treating substance use disorders.
Mol Psychiatry. 2025 Aug 19. doi: 10.1038/s41380-025-03168-w.
4
Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder.
PLoS One. 2025 May 7;20(5):e0321461. doi: 10.1371/journal.pone.0321461. eCollection 2025.
5
The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.
Psychiatry Res. 2025 Jun;348:116446. doi: 10.1016/j.psychres.2025.116446. Epub 2025 Mar 15.
6
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.
Eur Addict Res. 2024;30(5):302-320. doi: 10.1159/000540062. Epub 2024 Sep 25.
7
From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder.
Br J Clin Pharmacol. 2024 Dec;90(12):3036-3053. doi: 10.1111/bcp.16045. Epub 2024 Apr 16.
8
Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.
Front Psychiatry. 2024 Feb 22;15:1349565. doi: 10.3389/fpsyt.2024.1349565. eCollection 2024.
9
Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence.
Int Rev Psychiatry. 2023 Aug-Sep;35(5-6):377-396. doi: 10.1080/09540261.2023.2229430. Epub 2023 Jun 28.
10
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.
Front Pharmacol. 2023 Oct 11;14:1239159. doi: 10.3389/fphar.2023.1239159. eCollection 2023.

本文引用的文献

1
Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine.
Ther Adv Psychopharmacol. 2021 Jan 25;11:2045125320986634. doi: 10.1177/2045125320986634. eCollection 2021.
2
Applying the lessons of COVID-19 response to Canada's worsening opioid epidemic.
EClinicalMedicine. 2020 Dec;29:100633. doi: 10.1016/j.eclinm.2020.100633. Epub 2020 Nov 20.
3
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
JAMA Psychiatry. 2021 May 1;78(5):481-489. doi: 10.1001/jamapsychiatry.2020.3285.
4
Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis.
J Psychopharmacol. 2020 Oct;34(10):1079-1085. doi: 10.1177/0269881120919957. Epub 2020 May 25.
5
A life-course theory exploration of opioid-related maternal mortality in the United States.
Addiction. 2020 Nov;115(11):2079-2088. doi: 10.1111/add.15054. Epub 2020 Apr 12.
6
Collision of the COVID-19 and Addiction Epidemics.
Ann Intern Med. 2020 Jul 7;173(1):61-62. doi: 10.7326/M20-1212. Epub 2020 Apr 2.
7
Trajectories of retention in opioid agonist therapy in a Canadian setting.
Int J Drug Policy. 2020 Mar;77:102696. doi: 10.1016/j.drugpo.2020.102696. Epub 2020 Feb 9.
8
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.
Front Psychiatry. 2020 Jan 22;10:955. doi: 10.3389/fpsyt.2019.00955. eCollection 2019.
9
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials.
Front Psychiatry. 2020 Jan 21;10:943. doi: 10.3389/fpsyt.2019.00943. eCollection 2019.
10
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
Psychiatry Res. 2020 Feb;284:112749. doi: 10.1016/j.psychres.2020.112749. Epub 2020 Jan 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验